Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
R. J. Kelly, B. V. Landon, et al.
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
M. Schuler, K. Cuppens, et al.
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
P. G. M. D. Gooyer, Y. L. Verschoor, et al.
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCESO1 trial
J. Qin, L. Xue, et al.
Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial
S. Mukherjee, C. N. Hurt, et al.
